Mitoxantrone Accord (Mitoxantrone)

Mitoxantrone intercalates into DNA and stabilizes the topoisomerase II‑DNA complex, preventing the re‑ligation of DNA strands. This action creates double‑strand breaks, leading to apoptosis of rapidly dividing tumor cells. The drug also generates free radicals that add to its cytotoxic effect.

The dose of Mitoxantrone Accord is individualized by the prescribing oncologist based on the specific cancer type, disease stage, patient weight, renal and hepatic function, and prior treatment history. Only a qualified healthcare professional should determine the appropriate dosing schedule.

The safety of mitoxantrone in pregnancy and lactation has not been established. It is generally contraindicated in pregnant or nursing women because of potential fetal toxicity and excretion in breast milk. Women of child‑bearing potential should use effective contraception during treatment and for a period afterward as advised by their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and required import documentation.

Mitoxantrone belongs to the anthracenedione class and differs from anthracyclines such as doxorubicin in its chemical structure and toxicity profile. It is often chosen when a non‑anthracycline option is preferred, offering similar efficacy in certain leukemias and solid tumors but with a distinct risk of cardiotoxicity and secondary leukemia.

Mitoxantrone Accord should be stored at 2‑8 °C in a refrigerator, protected from light. The solution must not be frozen or shaken vigorously. Keep the vial in its original packaging until use to maintain stability and sterility.

The medication is supplied as an injectable solution for intravenous infusion. It is typically diluted in a compatible IV fluid and administered over a prescribed period, often ranging from several minutes to an hour, under close clinical monitoring for infusion‑related reactions.

The most serious adverse events include cardiotoxicity, which can lead to irreversible heart failure, severe myelosuppression that may cause life‑threatening infections or bleeding, and the rare possibility of therapy‑related secondary leukemia. Patients should be monitored regularly for cardiac function and blood counts.

Patients with known hypersensitivity to mitoxantrone or other anthracenediones, those with pre‑existing severe cardiac disease, uncontrolled infections, or significant bone‑marrow failure should not receive this drug. It is also contraindicated in pregnant or nursing women unless the benefits outweigh the risks.